A new FDA draft guidance is casting a spotlight on a "Holy Grail" in drug development: disease-modifying treatments for osteoarthritis. While most osteoarthritis drugs in the pipeline are intended to treat pain and other symptoms, a handful seek to alter the underlying pathology and structural progression of the disease.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?